Should I buy or sell Lyra Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYRA, but not buy additional shares or sell existing shares. View LYRA analyst ratings or view top-rated stocks .

What is Lyra Therapeutics' stock price target for 2024?

6 equities research analysts have issued 12 month price objectives for Lyra Therapeutics' stock. Their LYRA share price targets range from $0.50 to $15.00. On average, they expect the company's share price to reach $7.13 in the next twelve months. This suggests a possible upside of 1,599.7% from the stock's current price. View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts .

How have LYRA shares performed in 2024?

Lyra Therapeutics' stock was trading at $5.24 at the start of the year. Since then, LYRA shares have decreased by 92.0% and is now trading at $0.4192. View the best growth stocks for 2024 here .

Are investors shorting Lyra Therapeutics?

Lyra Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 333,600 shares, an increase of 49.6% from the March 31st total of 223,000 shares. Based on an average trading volume of 336,700 shares, the days-to-cover ratio is currently 1.0 days. View Lyra Therapeutics' Short Interest .

When is Lyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our LYRA earnings forecast .

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) released its earnings results on Tuesday, April, 30th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.09. The company had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.40 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 77.34% and a negative net margin of 4,099.82%.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE) , DocuSign (DOCU) , Intel (INTC) , OPKO Health (OPK) , Valero Energy (VLO) , Advanced Micro Devices (AMD) , CrowdStrike (CRWD) , Gilead Sciences (GILD) , Micron Technology (MU) and ONEOK (OKE) .

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rosalind Advisors Inc. (1.92%). Insiders that own company stock include C Ann Merrifield , Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc. View institutional ownership trends .

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

→ “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad)

Free LYRA Stock Alerts

$0.40

-0.02 (-5.24%)

(As of 12:16 PM ET)

Compare

Today's Range: $0.39
▼
$0.42
50-Day Range: $0.42
▼
$6.53
52-Week Range: $0.36
▼
$6.79

Volume: 4.42 million shs
Average Volume: 1.81 million shs
Market Capitalization: $24.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.13

Get Lyra Therapeutics alerts:

Lyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 1,599.7% Upside
$7.13 Price Target
Short Interest: Healthy
0.55% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.43
Based on 38 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.28) to ($1.23) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.21 out of 5 stars

Medical Sector

321st out of 903 stocks

Surgical & Medical Instruments Industry

43rd out of 95 stocks

4.0

Analyst's Opinion

Consensus Rating
Lyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Lyra Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Lyra Therapeutics' stock forecast and price target.

3.0

Short Interest

Percentage of Shares Shorted
0.55% of the outstanding shares of Lyra Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Lyra Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lyra Therapeutics has recently increased by 49.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lyra Therapeutics does not currently pay a dividend.
Dividend Growth
Lyra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LYRA.

1.4

News and Social Media Coverage

News Sentiment
Lyra Therapeutics has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 38 news articles for Lyra Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 15 people have searched for LYRA on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
5 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Lyra Therapeutics' insider trading history.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.28) to ($1.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lyra Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lyra Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lyra Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
Read more about Lyra Therapeutics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Could this Tiny Biotech End Disease Forever?

Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.

Access my full "Cut & Paste" profit analysis now.

About Lyra Therapeutics Stock (NASDAQ:LYRA)

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.